{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:51:31Z","timestamp":1791478291848,"version":"4.3.4"},"reference-count":88,"publisher":"Walter de Gruyter GmbH","issue":"10","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jpem-2026-0106_abs_001\">\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Congenital adrenal hyperplasia (CAH) comprises a group of rare autosomal recessive disorders and is a leading cause of primary adrenal insufficiency in children. Most cases are due to classic 21-hydroxylase deficiency. Earlier diagnosis has been made possible with newborn screening, which has also reduced the risk of adrenal crises. This review is based on a search of PubMed, Embase, Scopus, and Medline for articles published from 2000 to 2025, using the terms \u201ccongenital adrenal hyperplasia\u201d, \u201c21-hydroxylase deficiency\u201d, \u201cprimary adrenal insufficiency\u201d, and \u201csteroidogenesis\u201d with a focus on paediatric studies, clinical trials, systematic reviews, and consensus guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2026-0106_abs_002\">\n                    <jats:title>Content<\/jats:title>\n                    <jats:p>The aims of clinical management are appropriate glucocorticoid and mineralocorticoid replacement, prevention of adrenal crises, monitoring of growth, puberty, and metabolic health. The main challenges include balancing androgen suppression with minimising glucocorticoid overexposure and monitoring for long-term complications such as early bone maturation and testicular adrenal rest\u00a0tumours.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2026-0106_abs_010\">\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Diagnostic accuracy and genotype-phenotype correlations have improved through advances in biochemical testing and molecular genetics. Newer and adjunctive therapies, including modified-release hydrocortisone, CRF1 receptor antagonists, adrenal-targeted drugs, and experimental gene therapies, may further improve disease management and simplify treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2026-0106_abs_003\">\n                    <jats:title>Outlook<\/jats:title>\n                    <jats:p>Effective management of CAH in children requires balancing optimal hormonal control with minimising treatment-related adverse effects. Newer and future therapies are expected to improve physiological management and long-term outcomes. Further research is needed to enhance individualised care and support transition to adult services.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jpem-2026-0106","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T12:55:47Z","timestamp":1786020947000},"page":"961-976","source":"Crossref","is-referenced-by-count":0,"title":["Congenital adrenal hyperplasia in children: a comprehensive review of clinical spectrum, diagnostic strategies, and management approaches"],"prefix":"10.1515","volume":"39","author":[{"given":"Dinesh","family":"Giri","sequence":"first","affiliation":[{"name":"Bristol Royal Hospital for Children , Bristol , England, UK"},{"name":"University of Bristol , Bristol , England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Alderson","sequence":"additional","affiliation":[{"name":"Bristol Royal Hospital for Children , Bristol , England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munibah","family":"Bashir","sequence":"additional","affiliation":[{"name":"Alder Hey Children\u2019s Hospital , Liverpool , England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Shalaby","sequence":"additional","affiliation":[{"name":"Bristol Royal Hospital for Children , Bristol , England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Williams","sequence":"additional","affiliation":[{"name":"Alder Hey Children\u2019s Hospital , Liverpool , England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Park","sequence":"additional","affiliation":[{"name":"Alder Hey Children\u2019s Hospital , Liverpool , England, UK"},{"name":"University of Liverpool , Liverpool , England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"2026100815572200632_j_jpem-2026-0106_ref_001","doi-asserted-by":"crossref","unstructured":"Claahsen-van der Grinten, HL, Speiser, PW, Ahmed, SF, Arlt, W, Auchus, RJ, Falhammar, H, et al.. Congenital adrenal hyperplasia-current insights in pathophysiology, diagnostics, and management. Endocr Rev 2022;43:91\u2013159.","DOI":"10.1210\/endrev\/bnab016"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_002","doi-asserted-by":"crossref","unstructured":"Therrell, BL. Newborn screening for congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2001;30:15\u201330. https:\/\/doi.org\/10.1016\/s0889-8529(08)70017-3.","DOI":"10.1016\/S0889-8529(08)70017-3"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_003","doi-asserted-by":"crossref","unstructured":"White, PC, Speiser, PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000;21:245\u201391. https:\/\/doi.org\/10.1210\/edrv.21.3.0398.","DOI":"10.1210\/edrv.21.3.0398"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_004","doi-asserted-by":"crossref","unstructured":"Krone, N, Arlt, W. Genetics of congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metabol 2009;23:181\u201392. https:\/\/doi.org\/10.1016\/j.beem.2008.10.014.","DOI":"10.1016\/j.beem.2008.10.014"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_005","doi-asserted-by":"crossref","unstructured":"Miller, WL. Disorders in the initial steps of steroid hormone synthesis. J\u00a0Steroid Biochem Mol Biol 2017;165:18\u201337. https:\/\/doi.org\/10.1016\/j.jsbmb.2016.03.009.","DOI":"10.1016\/j.jsbmb.2016.03.009"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_006","doi-asserted-by":"crossref","unstructured":"Fl\u00fcck, CE, Pandey, AV. Clinical and biochemical consequences of P450 oxidoreductase deficiency. Endocr Dev 2011;20:63\u201379.","DOI":"10.1159\/000321221"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_007","doi-asserted-by":"crossref","unstructured":"Nordenstr\u00f6m, A, Lajic, S, Falhammar, H. Long-term outcomes of congenital adrenal hyperplasia. Endocrinol Metab (Seoul) 2022;37:587\u201398. https:\/\/doi.org\/10.3803\/enm.2022.1528.","DOI":"10.3803\/EnM.2022.1528"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_008","doi-asserted-by":"crossref","unstructured":"Lee, PA, Houk, CP. Review of outcome information in 46,XX patients with congenital adrenal hyperplasia assigned\/reared male. Int J Pediatr Endocrinol 2010;2010:982025. https:\/\/doi.org\/10.1186\/1687-9856-2010-982025.","DOI":"10.1186\/1687-9856-2010-982025"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_009","unstructured":"Witchel, SF. Non-classic congenital adrenal hyperplasia. Steroids 2017;131:52\u20136."},{"key":"2026100815572200632_j_jpem-2026-0106_ref_010","doi-asserted-by":"crossref","unstructured":"Auchus, RJ. Management considerations for non-classical congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2015;44:373\u201392.","DOI":"10.1016\/j.ecl.2015.02.002"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_011","doi-asserted-by":"crossref","unstructured":"Speiser, PW, Arlt, W, Auchus, RJ, Baskin, LS, Conway, GS, Merke, DP, et al.. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J\u00a0Clin Endocrinol Metab 2018;103:4043\u201388. https:\/\/doi.org\/10.1210\/jc.2018-01865.","DOI":"10.1210\/jc.2018-01865"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_012","doi-asserted-by":"crossref","unstructured":"Merke, DP, Bornstein, SR. Congenital adrenal hyperplasia. Lancet 2005;365:2125\u201336. https:\/\/doi.org\/10.1016\/s0140-6736(05)66736-0.","DOI":"10.1016\/S0140-6736(05)66736-0"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_013","doi-asserted-by":"crossref","unstructured":"Bonfig, W, Schmidt, H, Schwarz, HP. Growth patterns in the first three years of life in children with classical congenital adrenal hyperplasia diagnosed by newborn screening and treated with low doses of hydrocortisone. Horm Res Paediatr 2011;75:32\u20137. https:\/\/doi.org\/10.1159\/000316973.","DOI":"10.1159\/000316973"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_014","doi-asserted-by":"crossref","unstructured":"Mazzilli, R, Stigliano, A, Delfino, M, Olana, S, Zamponi, V, Iorio, C, et al.. The high prevalence of testicular adrenal rest tumors in adult men with congenital adrenal hyperplasia is correlated with ACTH levels. Front Endocrinol 2019;10:335. https:\/\/doi.org\/10.3389\/fendo.2019.00335.","DOI":"10.3389\/fendo.2019.00335"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_015","doi-asserted-by":"crossref","unstructured":"Hiort, O, Birnbaum, W, Marshall, L, W\u00fcnsch, L, Werner, R, Thyen, U, et al.. Management of disorders of sex development. Nat Rev Endocrinol 2014;10:520\u20139. https:\/\/doi.org\/10.1038\/nrendo.2014.108.","DOI":"10.1038\/nrendo.2014.108"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_016","unstructured":"White, PC. Neonatal screening for congenital adrenal hyperplasia. Nat Rev Endocrinol 2021;17:77\u201389."},{"key":"2026100815572200632_j_jpem-2026-0106_ref_017","doi-asserted-by":"crossref","unstructured":"Heather, NL, Nordenstr\u00f6m, A. Newborn Screening for CAH\u2014Challenges and Opportunities. Int J Neonatal Screen. 2021;7:11.","DOI":"10.3390\/ijns7010011"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_018","doi-asserted-by":"crossref","unstructured":"de Hora, MR, Heather, NL, Patel, T, Bresnahan, LG, Webster, D, Hofman, PL. Implementing steroid profiling by liquid chromatography\u2013tandem mass spectrometry improves newborn screening for congenital adrenal hyperplasia in New Zealand. Clin Endocrinol (Oxf). 2021;94:904\u201312.","DOI":"10.1111\/cen.14422"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_019","doi-asserted-by":"crossref","unstructured":"Hannah-Shmouni, F, Morissette, R, Sinaii, N, Elman, M, Prezant, TR, Chen, W, et al.. Revisiting the prevalence of nonclassic congenital adrenal hyperplasia in US Ashkenazi Jews and Caucasians. Genet Med 2017;19:1276\u20139. https:\/\/doi.org\/10.1038\/gim.2017.46.","DOI":"10.1038\/gim.2017.46"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_020","unstructured":"Witchel, SF. Non-classic congenital adrenal hyperplasia: current understanding. Curr Opin Pediatr 2024;36:476\u201384."},{"key":"2026100815572200632_j_jpem-2026-0106_ref_021","doi-asserted-by":"crossref","unstructured":"Moran, C, Azziz, R, Carmina, E, Dewailly, D, Fruzzetti, F, Iba\u00f1ez, L, et al.. 21-Hydroxylase-deficient nonclassic adrenal hyperplasia is a progressive disorder: a multicenter study. Am J Obstet Gynecol 2000;183:1468\u201374. https:\/\/doi.org\/10.1067\/mob.2000.108020.","DOI":"10.1067\/mob.2000.108020"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_022","doi-asserted-by":"crossref","unstructured":"Krone, N, Rose, IT, Willis, DS, Hodson, J, Wild, SH, Doherty, EJ, et al.. Genotype\u2013phenotype correlation in 153 adult patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J\u00a0Clin Endocrinol Metab 2013;98:E346\u201354.","DOI":"10.1210\/jc.2012-3343"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_023","doi-asserted-by":"crossref","unstructured":"Bose, HS, Sugawara, T, Strauss, JFIII, Miller, WL. The pathophysiology and genetics of congenital lipoid adrenal hyperplasia. N\u00a0Engl J Med 1996;335:1870\u20138. https:\/\/doi.org\/10.1056\/nejm199612193352503.","DOI":"10.1056\/NEJM199612193352503"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_024","doi-asserted-by":"crossref","unstructured":"Ishii, T, Tajima, T, Kashimada, K, Mukai, T, Tanahashi, Y, Katsumata, N, et al.. Clinical features of 57 patients with lipoid congenital adrenal hyperplasia. J\u00a0Clin Endocrinol Metab 2020;105:e3929\u201337. https:\/\/doi.org\/10.1210\/clinem\/dgaa557.","DOI":"10.1210\/clinem\/dgaa557"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_025","doi-asserted-by":"crossref","unstructured":"Simard, J, Ricketts, ML, Gingras, S, Soucy, P, Feltus, FA, Melner, MH. Molecular biology of the 3\u03b2-hydroxysteroid dehydrogenase\/\u03945\u2013\u03944 isomerase gene family. Endocr Rev 2005;26:525\u201382. https:\/\/doi.org\/10.1210\/er.2002-0050.","DOI":"10.1210\/er.2002-0050"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_026","doi-asserted-by":"crossref","unstructured":"Moisan, AM, Ricketts, ML, Tardy, V, Desrochers, M, M\u00e9barki, F, Chaussain, JL, et al.. New insight into the molecular basis of 3\u03b2-hydroxysteroid dehydrogenase deficiency. J\u00a0Clin Endocrinol Metab 1999;84:4410\u201325.","DOI":"10.1210\/jcem.84.12.6288"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_027","doi-asserted-by":"crossref","unstructured":"White, PC, Curnow, KM, Pascoe, L. Disorders of steroid 11\u00a0beta-hydroxylase isozymes. Endocr Rev 1994;15:421\u201338. https:\/\/doi.org\/10.1210\/edrv-15-4-421.","DOI":"10.1210\/edrv-15-4-421"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_028","doi-asserted-by":"crossref","unstructured":"Wang, D, Wang, J, Tong, T, Yang, Q. Non-classical 11\u03b2-hydroxylase deficiency caused by compound heterozygous mutations. J\u00a0Ovarian Res 2018;11:82. https:\/\/doi.org\/10.1186\/s13048-018-0450-8.","DOI":"10.1186\/s13048-018-0450-8"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_029","doi-asserted-by":"crossref","unstructured":"Miller, WL. The syndrome of 17,20 lyase deficiency. J\u00a0Clin Endocrinol Metab 2012;97:59\u201367. https:\/\/doi.org\/10.1210\/jc.2011-2161.","DOI":"10.1210\/jc.2011-2161"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_030","doi-asserted-by":"crossref","unstructured":"Idkowiak, J, Randell, T, Dhir, V, Patel, P, Shackleton, CH, Taylor, NF, et al.. Missense mutation in the human cytochrome b5 gene causes 46,XY disorder of sex development due to isolated 17,20 lyase deficiency. J\u00a0Clin Endocrinol Metab 2012;97:E465\u201375. https:\/\/doi.org\/10.1210\/jc.2011-2413.","DOI":"10.1210\/jc.2011-2413"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_031","doi-asserted-by":"crossref","unstructured":"Marsh, CA, Auchus, RJ. Fertility in patients with genetic deficiencies of cytochrome P450c17 (CYP17A1). Fertil Steril 2014;101:317\u201322.","DOI":"10.1016\/j.fertnstert.2013.11.011"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_032","doi-asserted-by":"crossref","unstructured":"Dean, B, Chrisp, GL, Quartararo, M, Maguire, AM, Hameed, S, King, BR, et al.. P450 oxidoreductase deficiency: a systematic review and meta-analysis. J\u00a0Clin Endocrinol Metab 2020;105:dgz255.","DOI":"10.1210\/clinem\/dgz255"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_033","doi-asserted-by":"crossref","unstructured":"Fukami, M, Nishimura, G, Homma, K, Nagai, T, Hanaki, K, Uematsu, A, et al.. Cytochrome P450 oxidoreductase deficiency: genotype\u2013phenotype correlations in 35 Japanese patients. J\u00a0Clin Endocrinol Metab 2009;94:1723\u201331.","DOI":"10.1210\/jc.2008-2816"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_034","doi-asserted-by":"crossref","unstructured":"Laue, K, Pogoda, HM, Daniel, PB, van Haeringen, A, Alanay, Y, von Ameln, S, et al.. Craniosynostosis and skeletal anomalies from defective retinoic acid degradation. Am J Hum Genet 2011;89:595\u2013606.","DOI":"10.1016\/j.ajhg.2011.09.015"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_035","doi-asserted-by":"crossref","unstructured":"Gomes, LG, Huang, N, Agrawal, V, Mendon\u00e7a, BB, Bachega, TA, Miller, WL. The common P450 oxidoreductase variant A503V is not a modifier gene for 21-hydroxylase deficiency. J\u00a0Clin Endocrinol Metab 2008;93:2913\u201316. https:\/\/doi.org\/10.1210\/jc.2008-0304.","DOI":"10.1210\/jc.2008-0304"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_065","doi-asserted-by":"crossref","unstructured":"Rink, RC, Metcalfe, PD, Cain, MP, Meldrum, KK, Kaefer, MA, Casale, AJ. Use of the mobilized sinus with total urogenital mobilization. J\u00a0Urol 2006;176:2205\u201311. https:\/\/doi.org\/10.1016\/j.juro.2006.07.078.","DOI":"10.1016\/j.juro.2006.07.078"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_036","doi-asserted-by":"crossref","unstructured":"David, M, Forest, MG. Prenatal treatment of congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency. J\u00a0Pediatr 1984;105:799\u2013803. https:\/\/doi.org\/10.1016\/s0022-3476(84)80310-8.","DOI":"10.1016\/S0022-3476(84)80310-8"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_037","doi-asserted-by":"crossref","unstructured":"Speiser, PW, Laforgia, N, Kato, K, Pereira, J, Khan, R, Yang, SY, et al.. First-trimester prenatal treatment and molecular genetic diagnosis of congenital adrenal hyperplasia (21-hydroxylase deficiency). J\u00a0Clin Endocrinol Metab 1990;70:838\u201348. https:\/\/doi.org\/10.1210\/jcem-70-4-838.","DOI":"10.1210\/jcem-70-4-838"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_038","doi-asserted-by":"crossref","unstructured":"Forest, MG, Nicolino, M, David, M, Morel, Y. The virilized female: endocrine background. BJU Int 2004;93:35\u201343. https:\/\/doi.org\/10.1111\/j.1464-410x.2004.04707.x.","DOI":"10.1111\/j.1464-410X.2004.04707.x"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_039","doi-asserted-by":"crossref","unstructured":"Tardy-Guidollet, V, Menassa, R, Costa, JM, David, M, Bouvattier, C, Baumann, C, et al.. New management strategy of pregnancies at risk of congenital adrenal hyperplasia using fetal sex determination in maternal serum: French cohort of 258 cases (2002\u20132011). J\u00a0Clin Endocrinol Metab 2014;99:1180\u20138. https:\/\/doi.org\/10.1210\/jc.2013-2895.","DOI":"10.1210\/jc.2013-2895"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_040","doi-asserted-by":"crossref","unstructured":"New, MI, Tong, YK, Yuen, T, Jiang, P, Pina, C, Chan, KC, et al.. Noninvasive prenatal diagnosis of congenital adrenal hyperplasia using cell-free fetal DNA in maternal plasma. J\u00a0Clin Endocrinol Metab 2014;99:E1022\u201330. https:\/\/doi.org\/10.1210\/jc.2014-1118.","DOI":"10.1210\/jc.2014-1118"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_041","doi-asserted-by":"crossref","unstructured":"New, MI, Abraham, M, Yuen, T, Lekarev, O. An update on prenatal diagnosis and treatment of congenital adrenal hyperplasia. Semin Reprod Med 2013;31:396\u20139. https:\/\/doi.org\/10.1055\/s-0032-1324723.","DOI":"10.1055\/s-0032-1324723"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_042","doi-asserted-by":"crossref","unstructured":"Simpson, JL, Rechitsky, S. Prenatal genetic testing and treatment for congenital adrenal hyperplasia. Fertil Steril 2019;111:21\u20133. https:\/\/doi.org\/10.1016\/j.fertnstert.2018.11.041.","DOI":"10.1016\/j.fertnstert.2018.11.041"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_043","doi-asserted-by":"crossref","unstructured":"Edgcomb, JB, Zima, B. Medication adherence among children and adolescents with severe mental illness: a systematic review and meta-analysis. J\u00a0Child Adolesc Psychopharmacol 2018;28:508\u201320. https:\/\/doi.org\/10.1089\/cap.2018.0040.","DOI":"10.1089\/cap.2018.0040"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_044","doi-asserted-by":"crossref","unstructured":"Quittner, AL, Modi, AC, Lemanek, KL, Ievers-Landis, CE, Rapoff, MA. Evidence-based assessment of adherence to medical treatments in pediatric psychology. J\u00a0Pediatr Psychol 2008;33:916\u201336. https:\/\/doi.org\/10.1093\/jpepsy\/jsm064.","DOI":"10.1093\/jpepsy\/jsm064"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_045","doi-asserted-by":"crossref","unstructured":"Alderson, J, Hamblin, RP, Crowne, EC. Psychological care of children and families with variations or differences in sex development. Horm Res Paediatr 2023;96:222\u20137. https:\/\/doi.org\/10.1159\/000524517.","DOI":"10.1159\/000524517"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_046","unstructured":"British Society for Paediatric Endocrinology and Diabetes (BSPED). Paediatric adrenal insufficiency: full guidance; 2023. Available from: https:\/\/www.bsped.org.uk\/media\/yqnpvaix\/bsped-paediatric-adrenal-insufficiency-guidance-2023.pdf."},{"key":"2026100815572200632_j_jpem-2026-0106_ref_047","doi-asserted-by":"crossref","unstructured":"Celsi, G, Kistner, A, Aizman, R, Ekl\u00f6f, AC, Ceccatelli, S, de Santiago, A, et al.. Prenatal dexamethasone causes oligonephronia, sodium retention and higher blood pressure in the offspring. Pediatr Res 1998;44:317\u201322. https:\/\/doi.org\/10.1203\/00006450-199809000-00009.","DOI":"10.1203\/00006450-199809000-00009"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_048","doi-asserted-by":"crossref","unstructured":"Seckl, JR, Miller, WL. How safe is long-term prenatal glucocorticoid treatment? JAMA 1997;277:1077\u20139. https:\/\/doi.org\/10.1001\/jama.1997.03540370067039.","DOI":"10.1001\/jama.1997.03540370067039"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_049","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Balsells, MM, Muthusamy, K, Smushkin, G, Lampropulos, JF, Elamin, MB, Abu Elnour, NO, et al.. Prenatal dexamethasone use for prevention of virilisation in pregnancies at risk for classical congenital adrenal hyperplasia: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 2010;73:436\u201344.","DOI":"10.1111\/j.1365-2265.2010.03826.x"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_050","doi-asserted-by":"crossref","unstructured":"Hirvikoski, T, Nordenstr\u00f6m, A, Wedell, A, Ritz\u00e9n, M, Lajic, S. Prenatal dexamethasone treatment of children at risk for congenital adrenal hyperplasia: the Swedish experience. J\u00a0Clin Endocrinol Metab 2012;97:1881\u20133. https:\/\/doi.org\/10.1210\/jc.2012-1222.","DOI":"10.1210\/jc.2012-1222"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_051","doi-asserted-by":"crossref","unstructured":"Wallensteen, L, Karlsson, L, Messina, V, Nordenstr\u00f6m, A, Lajic, S. Perturbed \u03b2-cell function and lipid profile after early prenatal dexamethasone exposure. J\u00a0Clin Endocrinol Metab 2020;105:e2439\u201348. https:\/\/doi.org\/10.1210\/clinem\/dgaa280.","DOI":"10.1210\/clinem\/dgaa280"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_052","doi-asserted-by":"crossref","unstructured":"Van\u2019t Westeinde, A, Karlsson, L, Nordenstr\u00f6m, A, Padilla, N, Lajic, S. First-trimester prenatal dexamethasone treatment and alterations in brain structure at adult age. J\u00a0Clin Endocrinol Metab 2020;105:dgaa340.","DOI":"10.1210\/clinem\/dgaa340"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_053","unstructured":"McCann-Crosby, B, Placencia, FX, Adeyemi-Fowode, O, Dietrich, J, Franciskovich, R, Gunn, S, et al.. Challenges in prenatal treatment with dexamethasone. Pediatr Endocrinol Rev 2018;16:186\u201393. https:\/\/doi.org\/10.17458\/per.vol16.2018.mcpa.dexamethasone."},{"key":"2026100815572200632_j_jpem-2026-0106_ref_054","doi-asserted-by":"crossref","unstructured":"Xu, L, Lin, W, Cai, L, Huang, H, Liang, J, Li, L, et al.. Efficacy and safety of prenatal dexamethasone treatment in offspring at risk for congenital adrenal hyperplasia: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 2020;92:109\u201323. https:\/\/doi.org\/10.1111\/cen.14126.","DOI":"10.1111\/cen.14126"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_055","doi-asserted-by":"crossref","unstructured":"Merke, DP, Mallappa, A, Arlt, W, Brac de la Perri\u00e8re, A, Lind\u00e9n Hirschberg, A, Juul, A, et al.. Modified-release hydrocortisone in congenital adrenal hyperplasia. J\u00a0Clin Endocrinol Metab 2021;106:e2063\u201377. https:\/\/doi.org\/10.1210\/clinem\/dgab051.","DOI":"10.1210\/clinem\/dgab051"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_056","doi-asserted-by":"crossref","unstructured":"Arlt, W, Brac de la Perri\u00e8re, A, Hirschberg, AL, Merke, DP, Newell-Price, JDC, Prete, A, et al.. Long-term outcomes in patients with congenital adrenal hyperplasia treated with hydrocortisone modified-release hard capsules. Eur J Endocrinol 2025;193:76\u201384. https:\/\/doi.org\/10.1093\/ejendo\/lvaf130.","DOI":"10.1093\/ejendo\/lvaf130"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_057","doi-asserted-by":"crossref","unstructured":"Auer, MK, Nordenstr\u00f6m, A, Lajic, S, Reisch, N. Congenital adrenal hyperplasia. Lancet 2023;401:227\u201344. https:\/\/doi.org\/10.1016\/s0140-6736(22)01330-7.","DOI":"10.1016\/S0140-6736(22)01330-7"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_058","doi-asserted-by":"crossref","unstructured":"Lee, A. Crinecerfont: first approval. Drugs 2025;85:839\u201343. https:\/\/doi.org\/10.1007\/s40265-025-02165-1.","DOI":"10.1007\/s40265-025-02165-1"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_059","doi-asserted-by":"crossref","unstructured":"Sarafoglou, K, Kim, MS, Lodish, M, Felner, EI, Martinerie, L, Nokoff, NJ, et al.. Phase 3 trial of crinecerfont in pediatric congenital adrenal hyperplasia. N\u00a0Engl J Med 2024;391:493\u2013503. https:\/\/doi.org\/10.1056\/nejmoa2404655.","DOI":"10.1056\/NEJMoa2404655"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_060","doi-asserted-by":"crossref","unstructured":"Auchus, RJ, Buschur, EO, Chang, AY, Hammer, GD, Ramm, C, Madrigal, D, et al.. Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency. J\u00a0Clin Endocrinol Metab 2014;99:2763\u201370. https:\/\/doi.org\/10.1210\/jc.2014-1258.","DOI":"10.1210\/jc.2014-1258"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_061","doi-asserted-by":"crossref","unstructured":"Wright, C, O\u2019Day, P, Alyamani, M, Sharifi, N, Auchus, RJ. Abiraterone acetate treatment lowers 11-oxygenated androgens. Eur J Endocrinol 2020;182:413\u201321. https:\/\/doi.org\/10.1530\/eje-19-0905.","DOI":"10.1530\/EJE-19-0905"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_062","doi-asserted-by":"crossref","unstructured":"Merke, DP, Mallappa, A, Parker, M, Sukin, C, Kulkarni, SE, Keil, MF, et al.. Adult height following prepubertal treatment with antiandrogen, aromatase inhibitor, and reduced hydrocortisone in congenital adrenal hyperplasia. J\u00a0Clin Endocrinol Metab 2025;110:e2171\u201382. https:\/\/doi.org\/10.1210\/clinem\/dgae824.","DOI":"10.1210\/clinem\/dgae824"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_063","doi-asserted-by":"crossref","unstructured":"Al-Rayess, H, Wiersma, R, Turner, LE, Palzer, E, Mercado Munoz, Y, Sarafoglou, K. Anastrozole improves height outcomes in growing children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J\u00a0Clin Endocrinol Metab 2025;110:e2198\u2013207. https:\/\/doi.org\/10.1210\/clinem\/dgae771.","DOI":"10.1210\/clinem\/dgae771"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_064","doi-asserted-by":"crossref","unstructured":"Rink, RC, Whittam, BM. Treatment and outcome of congenital adrenal hyperplasia: current reconstructive surgery. In: New, MI, editor. Genetic steroid disorders. 2nd ed. San Diego, CA: Academic Press; 2023:179\u201385 pp.","DOI":"10.1016\/B978-0-12-821424-4.00016-2"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_066","doi-asserted-by":"crossref","unstructured":"Rink, RC, Metcalfe, PD, Kaefer, MA, Casale, AJ, Meldrum, KK, Cain, MP. Partial urogenital mobilization: a limited proximal dissection. J\u00a0Pediatr Urol 2006;2:351\u20136. https:\/\/doi.org\/10.1016\/j.jpurol.2006.04.002.","DOI":"10.1016\/j.jpurol.2006.04.002"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_067","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez, R, Ludwikowski, BM. Is it beneficial to include congenital adrenal hyperplasia among disorders of sex development? Front Pediatr 2018;6:344. https:\/\/doi.org\/10.3389\/fped.2018.00344.","DOI":"10.3389\/fped.2018.00344"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_068","doi-asserted-by":"crossref","unstructured":"Binet, A, Lardy, H, Geslin, D, Francois-Fiquet, C, Poli-Merol, ML. Should we question early feminizing genitoplasty for patients with congenital adrenal hyperplasia and XX karyotype? J\u00a0Pediatr Surg 2016;51:465\u20138. https:\/\/doi.org\/10.1016\/j.jpedsurg.2015.10.004.","DOI":"10.1016\/j.jpedsurg.2015.10.004"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_069","doi-asserted-by":"crossref","unstructured":"Shalaby, M, Chandran, H, Elford, S, Kirl, J, McCarthy, L. Recommendations of patients and families of girls with 46XX congenital adrenal hyperplasia in the United\u00a0Kingdom regarding the timing of surgery. Pediatr Surg Int 2021;37:137\u201343. https:\/\/doi.org\/10.1007\/s00383-020-04780-3.","DOI":"10.1007\/s00383-020-04780-3"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_070","doi-asserted-by":"crossref","unstructured":"Graves, LE, Viswanath, L, van Dijk, EB, Zhu, E, Koyyalamudi, S, Wotton, T, et al.. Targeted editing of the 21-hydroxylase locus confers durable therapeutic effect in a murine model of congenital adrenal hyperplasia. Mol Ther 2025;34:1138\u201351.","DOI":"10.1016\/j.ymthe.2025.11.011"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_071","doi-asserted-by":"crossref","unstructured":"Graves, LE, van Dijk, EB, Zhu, E, Koyyalamudi, S, Wotton, T, Sung, D, et al.. AAV-delivered hepato-adrenal cooperativity in steroidogenesis: implications for gene therapy for congenital adrenal hyperplasia. Mol Ther Methods Clin Dev 2024;32:101232. https:\/\/doi.org\/10.1016\/j.omtm.2024.101232.","DOI":"10.1016\/j.omtm.2024.101232"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_072","doi-asserted-by":"crossref","unstructured":"Graves, LE, Torpy, DJ, Coates, PT, Alexander, IE, Bornstein, SR, Clarke, B. Future directions for adrenal insufficiency: cellular transplantation and genetic therapies. J\u00a0Clin Endocrinol Metab 2023;108:1273\u201389. https:\/\/doi.org\/10.1210\/clinem\/dgac751.","DOI":"10.1210\/clinem\/dgac751"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_073","doi-asserted-by":"crossref","unstructured":"Engels, M, Span, PN, van Herwaarden, AE, Sweep, FCGJ, Stikkelbroeck, NMML, Claahsen-van der Grinten, HL. Testicular adrenal rest tumors: current insights. Endocr Rev 2019;40:973\u201387.","DOI":"10.1210\/er.2018-00258"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_074","doi-asserted-by":"crossref","unstructured":"Auer, MK, B\u00fcy\u00fckerzurmulu, D, Lottspeich, C, Bidlingmaier, M, Rieger, E, Nowotny, H, et al.. Prevalence of adrenal rest tumors and course of gonadal dysfunction in men with congenital adrenal hyperplasia. Eur J Endocrinol 2024;191:370\u201380.","DOI":"10.1093\/ejendo\/lvae112"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_075","doi-asserted-by":"crossref","unstructured":"Vaid, S, Kulkarni, S, Marko, J, Sinaii, N, Sukin, C, Burkardt, D, et al.. Longitudinal characterization and sonographic staging of testicular adrenal rest tumors. J\u00a0Clin Endocrinol Metab 2026;113:698\u2013706.","DOI":"10.1210\/clinem\/dgaf498"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_076","doi-asserted-by":"crossref","unstructured":"Schr\u00f6der, MAM, Neac\u015fu, M, Adriaansen, BPH, Sweep, FCGJ, Ahmed, SF, Ali, SR, et al.. Hormonal control during infancy and testicular adrenal rest tumor development in males with congenital adrenal hyperplasia. Eur J Endocrinol 2023;189:460\u20138. https:\/\/doi.org\/10.1093\/ejendo\/lvad143.","DOI":"10.1093\/ejendo\/lvad143"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_077","doi-asserted-by":"crossref","unstructured":"Bouvattier, C, Esterle, L, Renoult-Pierre, P, de la Perri\u00e8re, AB, Illouz, F, Kerlan, V, et al.. Clinical outcome and testicular function in 219 adult men born with classic 21-hydroxylase deficiency. J\u00a0Clin Endocrinol Metab 2015;100:2303\u201313.","DOI":"10.1210\/jc.2014-4124"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_078","doi-asserted-by":"crossref","unstructured":"Cabrera, MS, Vogiatzi, MG, New, MI. Long-term outcome in adult males with classic congenital adrenal hyperplasia. J\u00a0Clin Endocrinol Metab 2001;86:3070\u20138. https:\/\/doi.org\/10.1210\/jcem.86.7.7668.","DOI":"10.1210\/jc.86.7.3070"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_079","doi-asserted-by":"crossref","unstructured":"Torky, A, Sinaii, N, Jha, S, Desai, J, El-Maouche, D, Mallappa, A, et al.. Cardiovascular disease risk factors and metabolic morbidity in congenital adrenal hyperplasia. J\u00a0Clin Endocrinol Metab 2021;106:e5247\u201357.","DOI":"10.1210\/clinem\/dgab133"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_080","doi-asserted-by":"crossref","unstructured":"Engberg, H, Nordenstr\u00f6m, A, Hirschberg, AL. Clinical manifestations and challenges in adolescent and adult females with classic congenital adrenal hyperplasia. J\u00a0Clin Endocrinol Metab 2025;110:S37\u201345. https:\/\/doi.org\/10.1210\/clinem\/dgae696.","DOI":"10.1210\/clinem\/dgae696"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_081","doi-asserted-by":"crossref","unstructured":"Pofi, R, Ji, X, Krone, NP, Tomlinson, JW. Long-term health consequences of congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 2024;101:318\u201331. https:\/\/doi.org\/10.1111\/cen.14967.","DOI":"10.1111\/cen.14967"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_082","doi-asserted-by":"crossref","unstructured":"Pitts, L, Armstrong, A, Fleming, L, Hallowell, S, Landier, W, Odom, JN, et al.. Healthcare transition of individuals with congenital adrenal hyperplasia. Horm Res Paediatr 2025;98:1\u201310.","DOI":"10.1159\/000547790"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_083","doi-asserted-by":"crossref","unstructured":"Bharadwaj, M, Tyagi, V, Dabas, A, Yadav, S. Quality of life and disease perceptions in caregivers of children with congenital adrenal hyperplasia. Med J Armed Forces India 2023;79:S26\u20139. https:\/\/doi.org\/10.1016\/j.mjafi.2021.08.016.","DOI":"10.1016\/j.mjafi.2021.08.016"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_084","doi-asserted-by":"crossref","unstructured":"Lundberg, T, Lindstr\u00f6m, A, Roen, K, Hegarty, P. From knowing nothing to knowing what, how and now: parents\u2019 experiences of caring for their children with congenital adrenal hyperplasia. J\u00a0Pediatr Psychol 2017;42:520\u20139.","DOI":"10.1093\/jpepsy\/jsw001"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_085","doi-asserted-by":"crossref","unstructured":"Bouliari, A, Fleming, L, Hinton, I, Matos, D, McCoy, J, Holroyd, L, et al.. Living with congenital adrenal hyperplasia: insights on quality of life. Front Endocrinol (Lausanne) 2026;17:1795860. https:\/\/doi.org\/10.3389\/fendo.2026.1795860.","DOI":"10.3389\/fendo.2026.1795860"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_086","doi-asserted-by":"crossref","unstructured":"Sumi\u0144ska, M, Bogusz-G\u00f3rna, K, Wegner, D, Fichna, M. Non-classic disorder of adrenal steroidogenesis and clinical dilemmas in 21-hydroxylase deficiency combined with backdoor androgen pathway. Int J Mol Sci 2020;21:4622. https:\/\/doi.org\/10.3390\/ijms21134622.","DOI":"10.3390\/ijms21134622"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_087","doi-asserted-by":"crossref","unstructured":"Sarafoglou, K, Merke, DP, Reisch, N, Claahsen-van der Grinten, H, Falhammar, H, Auchus, RJ. Interpretation of steroid biomarkers in 21-hydroxylase deficiency. J\u00a0Clin Endocrinol Metab 2023;108:2154\u201375.","DOI":"10.1210\/clinem\/dgad134"},{"key":"2026100815572200632_j_jpem-2026-0106_ref_088","doi-asserted-by":"crossref","unstructured":"Sarafoglou, K, Auchus, RJ. Future directions in the management of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J\u00a0Clin Endocrinol Metab 2025;110:S74\u201387. https:\/\/doi.org\/10.1210\/clinem\/dgae759.","DOI":"10.1210\/clinem\/dgae759"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2026-0106\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2026-0106\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:58:35Z","timestamp":1791475115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2026-0106\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":88,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,7,27]]},"published-print":{"date-parts":[[2026,10,26]]}},"alternative-id":["10.1515\/jpem-2026-0106"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2026-0106","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"value":"0334-018X","type":"print"},{"value":"2191-0251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]}}}